Silodosin NDC 31722-635

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-635Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0635Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
31722-635-30	31722063530	30 CAPSULE in 1 BOTTLE (31722-635-30)Marketed from Feb 14, 2020
31722-635-31	31722063531	30 CAPSULE in 1 BOTTLE (31722-635-31)Marketed from Feb 14, 2020
31722-635-90	31722063590	90 CAPSULE in 1 BOTTLE (31722-635-90)Marketed from Feb 14, 2020
31722-635-91	31722063591	90 CAPSULE in 1 BOTTLE (31722-635-91)Marketed from Feb 14, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Silodosin
Generic name (nonproprietary): silodosin
Active ingredients: Silodosin — 4 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Camber Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204793
Marketing start: Feb 14, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 31722-635_1a1f75e4-0d3a-55a0-e063-6294a90af183SPL ID 1a1f75e4-0d3a-55a0-e063-6294a90af183SPL set ID b9880aad-5fbe-470b-a7a0-d963ba4bc98bRxCUI 809477, 826612UNII CUZ39LUY82UPC 0331722636308, 0331722635905, 0331722636902, 0331722635301
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N431722063530 followed by a unit qualifier and the quantity

Package 31722-0635-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 5, 2024.

Indications (excerpt from the label)

Silodosin capsules, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see CLINICAL STUDIES ( 14 )]. Silodosin capsules are not indicated for the treatment of hypertension. Silodosin capsules, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin capsules are not indicated for the treatment of hypertension. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204793

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204793
Product	Strength	Form · route	Labeler	Product NDC
Silodosin	Silodosin 8 mg/1	CapsuleOral	Camber Pharmaceuticals, Inc.	31722-636